Amgen's big cardiovascular bet with Cytokinetics hits PhIII primary but dramatically disappoints investors
A closely watched heart drug from Amgen and Cytokinetics has both hit the primary endpoint on a major trial and dramatically disappointed investors.
In the 8,250-person study, the drug reduced the odds of hospitalization or other urgent care for heart failure by 8%, a statistically significant result. But the drug failed to help high-risk patients live longer, an endpoint that analysts had been following as the key marker for whether the drug could make a large impact.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
